Menu

New COVID-19 Frontline Infusion Therapies: Optimizing Health Outcomes for High-Risk Patients

When:
June 25, 2021 @ 3:33 pm – June 25, 2022 @ 4:33 pm
2021-06-25T15:33:00+00:00
2022-06-25T16:33:00+00:00

New COVID-19 Frontline Infusion Therapies: Optimizing Health Outcomes for High-Risk Patients

 

Program Modules

Module 1: Infusion  Module 2: Prevention  Module 3: Treatment

FACULTY

Valentina (Tina) Stosor, MD
Professor
Divisions of Infectious Diseases and Organ Transplantation
Northwestern University Feinberg School of Medicine
Chicago, IL

 

Scroll to Top
Menu

Updates in the Treatment and Prevention of COVID-19​

Molnupiravir, an Oral Antiviral, Reduced the Risk of Hospitalization or Death in Patients with Mild-to-Moderate COVID-19

Molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death by 50% in an interim analysis of the phase 3 MOVe-OUT trial. The planned analysis evaluated data from 775 at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19. All patients enrolled had at least one risk factor associated with poor COVID-19 outcomes and were randomized within 5 days of symptom onset. At day 29, 7.3% of patients who received molnupiravir were either hospitalized or died, compared with 14.1% of placebo-treated patients (P= .0012). No deaths were reported in patients receiving molnupiravir, compared with 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Discontinuation due to adverse events was lower with molnupiravir (1.3%) versus placebo (3.4%).

Reference:

https://www.contagionlive.com/view/molnupiravir-could-become-first-authorized-covid-19-pill